Group items tagged

The intent of the FY19 FITBIR Analysis Award is to leverage this data to identify actionable insights for the diagnosis, management, and treatment of TBI. The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public. The anticipated total costs budgeted for the entire period of performance for an FY19 JPC-6/CCCRP PH/TBI FITBIR Analysis Award will not exceed $750,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. The JPC-6/CCCRP expects to allot approximately $3M of the FY19 PH/TBIRP appropriation to fund approximately 4 FITBIR Analysis Award applications. Funding of applications received is contingent upon the availability of Federal funds for this program as well as the number of applications received, the quality and merit of the applications as evaluated by scientific and programmatic review, and the requirements of the Government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY19 FITBIR Analysis Award funding opportunity will be funded with FY19 funds, which will expire for use on September 30, 2025

The intent of the FY17 ERP IDA is to solicit research to understand the magnitude and underlying mechanisms of PTE. The FY17 ERP IDA offers two levels of funding. Funding Level I is intended to support high-risk or high-gain research from Principal Investigators (PIs) at or above the level of a postdoctoral fellow (or equivalent), but below the level of Assistant Professor (or equivalent). Note that PIs submitting Funding Level I applications will be required to verify their eligibility for this award. Funding Level II is intended to support a more mature, hypothesis-driven research project. To be considered for an FY17 ERP IDA Funding Level II, the PI must be an independent investigator at or above the level of Assistant Professor (or equivalent). While not required, applications to either Funding Level I or II should provide relevant preliminary data. Preliminary data for either Funding Level may come from the PI's published work, pilot data, or from peer-reviewed literature. The requested budget level should be appropriate for the scope of research proposed.For Funding Level I:The anticipated direct costs budgeted for the entire period of performance for an FY17 ERP IDA award will not exceed $300,000. The maximum period of performance is 2 years. For Funding Level II:The anticipated direct costs budgeted for the entire period of performance for an FY17 ERP IDA award will not exceed $500,000. The maximum period of performance is 3 years. FY17 ERP IDA Focus Areas: The research impact for the FY17 ERP IDA is expected to benefit the military, Veteran, and civilian communities.

The SCIMS program is designed to provide a multidisciplinary system of rehabilitation care specifically to meet the needs of individuals with SCI. To be eligible for a SCI Model Systems grant, an applicant institution must encompass a continuum of care for people with SCI, including emergency medical services, acute care services, acute medical rehabilitation services, and post-acute services. For purposes of this program, SCI is defined as a clinically discernible degree of neurologic impairment of the spinal cord following a traumatic event. NIDILRR currently supports 14 SCIMS centers through this program. The funding for these Centers is primarily used to conduct SCI research and to collect and send data to the SCIMS longitudinal database. SCIMS Centers will be funded at varying amounts up to the maximum award based on the numbers of subjects eligible for follow-up in the existing SCIMS longitudinal database. Existing centers with significantly larger numbers of subjects will receive higher funding within the specified range, as determined by NIDILRR after the applicant is selected for funding. Applicants provide detailed budgets for each research project and for data collection costs associated with the longitudinal database. Funding will be determined individually for each successful applicant, up to the maximum allowed, based upon the documented workload associated with the follow-up data collection, the other costs of the grant, and the overall budgetary limits of the program

Sigma Xi, a society of research scientists and engineers that rewards excellence in research and cooperation among scientists in all fields, has been providing undergraduate and graduate students with valuable educational experiences and financial support for more than eighty years. By encouraging close working relationships between students and faculty, the society promotes scientific achievement through hands-on learning. Through the Sigma Xi Grants-in-Aid of Research program, the society awards grants of up to $1,000 to students from all areas of the sciences and engineering. Designated funds from the National Academy of Sciences allow for grants of up to $5,000 for astronomy research and $2,500 for vision-related research. Funding can support travel expenses or nonstandard laboratory equipment necessary to complete a specific research project. While membership in Sigma Xi is not a requirement for applying for funding, approximately 75 percent of Grants-in-Aid of Research funds are restricted for use by dues-paying student members or students whose project advisor is a dues-paying member. Students from any country are eligible to receive funding. Complete program guidelines and application instructions are available on the Sigma Xi Web site.

The goal of this FOA is to enhance the diversity of the drug abuse research workforce by providing dissertation awards on topics related to the study of basic and clinical neuroscience, development, epidemiology, prevention, treatment, services, or women and sex/gender differences as they relate to drug abuse. This support will enhance the pool of highly talented drug abuse scientists who conduct research within the funding priority areas (http://www.drugabuse.gov/funding/funding-priorities) or in the NIDA strategic plan (https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan). Applications are encouraged from doctoral candidates in a variety of academic disciplines and programs. This program will ultimately facilitate the entry of promising new investigators into the field of drug abuse research and promote transdisciplinary collaborations. This award is for up to two years of support for the completion of the doctoral dissertation research project.

The goal of this FOA is to enhance the diversity of the drug abuse research workforce by providing dissertation awards on topics related to the study of basic and clinical neuroscience, development, epidemiology, prevention, treatment, services, or women and sex/gender differences as they relate to drug abuse. This support will enhance the pool of highly talented drug abuse scientists who conduct research within the funding priority areas (http://www.drugabuse.gov/funding/funding-priorities) or in the NIDA strategic plan (https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan). Applications are encouraged from doctoral candidates in a variety of academic disciplines and programs. This program will ultimately facilitate the entry of promising new investigators into the field of drug abuse research and promote transdisciplinary collaborations. This award is for up to two years of support for the completion of the doctoral dissertation research project.

This NIH Funding Opportunity Announcement (FOA), supported by funds from the NIH Common Fund (Common Fund) and managed by the Office of the Director and participating NIH Institute(s) and Center(s) of the Stimulating Peripheral Activity to Relieve Conditions (SPARC) program, solicits U18 Research Demonstration Cooperative Agreement applications to develop new and/or enhance existing tools and technologies tailored to elucidate the neurobiology and neurophysiology underlying autonomic control of internal organs in health or disease, which will ultimately inform next generation neuromodulation therapies. These awards will establish feasibility for further technology development in any future SPARC initiatives.  Additionally, the technologies developed through these awards are expected to lay the groundwork for more systematic facilitation of biological mapping activities in any future SPARC initiatives.  

This NIH Funding Opportunity Announcement (FOA), supported by funds from the NIH Common Fund (Common Fund) and managed by the Office of the Director and participating NIH Institute(s) and Center(s) of the Stimulating Peripheral Activity to Relieve Conditions (SPARC) program, solicits U18 Research Demonstration Cooperative Agreement applications to develop new and/or enhance existing tools and technologies tailored to elucidate the neurobiology and neurophysiology underlying autonomic control of internal organs in health or disease, which will ultimately inform next generation neuromodulation therapies. These awards will establish feasibility for further technology development in any future SPARC initiatives.  Additionally, the technologies developed through these awards are expected to lay the groundwork for more systematic facilitation of biological mapping activities in any future SPARC initiatives.  

Reissue of RFA-NS-18-032. The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support and increased flexibility to Program Directors (PDs) /Principal Investigators (PIs) whose records of research achievement demonstrate their ability to make major contributions to neuroscience. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PI's recent NINDS support (Part 2, Section II) This greater funding stability will provide eligible investigators at nearly all career stages increased freedom and flexibility, allowing them to be more adventurous in their research, take greater risks, embark upon research that breaks new ground, undertake research projects that require a longer timeframe, and/or extend previous discoveries in new directions. Research supported through the RPA must be within the scope of the NINDS mission (http://www.ninds.nih.gov/about_ninds/mission.htm). Research activities outside of the NINDS mission, or traditionally supported by another NIH Institute or Center will not be considered through this program. Other anticipated benefits of the RPA include: A more stable funding environment, facilitating the pursuit of longer-term research goals; Flexible funding, enabling investigators to pursue research opportunities as they arise, not tied to specific aims; Reduced time spent writing grant applications and managing multiple grant awards, thereby allowing investigators to spend more time conducting and overseeing research; and More time for PDs/PIsto mentor junior scientists. Eligibility to apply through this FOA is limited to investigators who currently have at least one active NINDS R01 or R01 equivalent grant (defined here as R00, R01, R37, R56, DP1 or DP2 awards), and who have had an active R01 equivalent grant from NINDS in each of the past 5 years, with no more than one of those years in a no cost extension.

The International Research Network Connections (IRNC) program supports high-performance network connectivity required by international science and engineering research and education collaborations involving the NSF research community. NSF expects to make 1-2 awards to link U.S. research networks with peer networks in Europe and Africa and leverage existing international network connectivity. High-performance network connections funded by this program are intended to support science and engineering research and education applications, and preference will be given to solutions that provide the best economy of scale and demonstrate the ability to support the largest communities of interest with the broadest services. Funded projects will assist the U.S. research and education community by enabling state-of-the-art international network services and access to increased collaboration and data services. Through extended international network connections, additional research and production network services will be enabled, complementing those currently offered or planned by domestic research networks.

The International Research Network Connections (IRNC) program supports high-performance network connectivity required by international science and engineering research and education collaborations involving the NSF research community. NSF expects to make 1-2 awards to link U.S. research networks with peer networks in Europe and Africa and leverage existing international network connectivity. High-performance network connections funded by this program are intended to support science and engineering research and education applications, and preference will be given to solutions that provide the best economy of scale and demonstrate the ability to support the largest communities of interest with the broadest services. Funded projects will assist the U.S. research and education community by enabling state-of-the-art international network services and access to increased collaboration and data services. Through extended international network connections, additional research and production network services will be enabled, complementing those currently offered or planned by domestic research networks.

The Technology Validation and Start-Up Fund (the "Program") provides grants to transition technology from Ohio research institutions into the marketplace through Ohio start-up companies. Ohio research institutions may apply for funding for validation (e.g. viability testing, prototyping, etc.) of their unlicensed technologies. Ohio start-up companies may apply for funding to advance towards commercialization a technology they intend to license from an Ohio research institution.

The Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30) award will support students at institutions without formal NIH-funded institutional predoctoral dual-degree training programs. The purpose of this FOA is to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g., DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), and who intend careers as physician/clinician-scientists. Applicants must propose an integrated research and clinical training plan and a dissertation research project in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The fellowship experience is expected to clearly enhance the individuals' potential to develop into a productive, independent physician/clinician-scientist. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

The Esther A. & Joseph Klingenstein Fund, in partnership with the Simons Foundation, has announced the opening of its 2019 competition for research fellowships in the neurosciences. Previously known as the Klingenstein Fellowship Awards in the Neurosciences, this year's awards are the second from the joint initiative. The awards are presented to highly promising early-career scientists at a point in their careers when funding can be a challenge and are designed to promote higher-risk, and potentially higher-reward, projects.

The Alzheimer's Drug Discovery Foundation has issued a Request for Proposals for its Preclinical Drug Discovery program. Through the program, grants of up to $600,000 over two years will be awarded to promising preclinical drug discovery programs relevant to Alzheimer's disease, related dementias, and cognitive aging. Preclinical research funding priorities include high throughput screening, medicinal chemistry hit-to-lead development and optimization, in vitro and in vivo efficacy studies, ADME, toxicology, pharma-cokinetics and pharma-co-dynamics, and in vivo proof-of-concept with lead compounds and biologics. Program areas of particular interest include new chemical compounds for Alzheimer's disease, preclinical proof-of-concept, and re-purposing. With regards to potential drug targets, ADDF is interested in novel targets that include but are not limited to neuro-inflammation, protein degradation/autophagy, growth factor signaling, synaptic function/morphology, calcium regulation, energy utilization/mitochondria function, insulin sensitivity, epigenetics, ApoE function and cholesterol metabolism, vascular injury and the blood-brain barrier interface, cognitive enhancers, myelin changes, ischemia and oxidative stress, and tau-related toxicities. To be eligible, applicants must be academic investigators seeking to create and support innovative translational programs in academic medical centers and universities; biotechnology companies with programs dedicated to Alzheimer's disease translational development; and new biotechnology company spinouts or existing biotechnology companies that demonstrate a clear need for nonprofit funding. Funding is provided through program-related investments (PRIs) that require a return on investment based on scientific and/or business milestones.

The Michael J. Fox Foundation works tirelessly to accelerate promising research toward breakthroughs for Parkinson's patients. While our strong emphasis is on funding translational and clinical research, we also support high-risk/high-reward discovery work. In addition to funding, awardees benefit from working with our internal research staff and broad network of scientific and industry advisors. Targeted Funding Opportunities | Application Deadline: May 31, 2018: 1. Alpha-synuclein Biology and Therapies 2. GBA Biology and Therapies 3. Biomarkers of Protein Handling/Autophagy, Exosomes and Lipids 4. Non-Pharmacological Interventions for Gait and Balance Disturbances

The Ethics Education in Science and Engineering (EESE) program funds research and educational projects that improve ethics education in all fields of science and engineering that NSF supports, with priority consideration given to interdisciplinary, inter-institutional, and international contexts.  Although the primary focus is on improving ethics education for graduate students in NSF-funded fields, the proposed programs may benefit advanced undergraduates as well.

To allow investigators time to plan and develop applications, the TSCRP is providing its strategic plan for award mechanisms to be offered in 2013 should funding become available. Congressional funds for the FY13 TSCRP have not yet been appropriated, and this document is not to be construed as an obligation by the government; there is no guarantee of funding for these planned mechanisms. Areas of Focus: The FY13 TSCRP encourages research projects applications that specifically address the critical needs of theTSC community in the following areas of focus: Genetic, epigenetic, and non-genetic modifiers of TSC. Identification and development of preclinical models and therapeutic strategies (e.g., cytotoxic agents, combination therapies). Identifying biomarkers for early detection, prognosis, and prediction of treatment outcomes (such as serum markers, imaging, electrophysiology, prenatal testing, and pharmacogenetics). Impact of TSC manifestations in adults (e.g., care management, age-specific pathogenesis, epidemiology, renal, reproductive issues, and lymphangioleiomyomatosis [LAM])). Long-term benefits and effects of mTOR inhibitors or other agents. Novel strategies for diagnosis, treatment, and prevention of TSC manifestations including those geared toward early identification and intervention. Understanding the cellular and molecular mechanisms of TSC and LAM pathogenesis. Understanding the mechanism and improving the treatment of epilepsy in TSC. Understanding the mechanism and improving treatment of TSC-associated neurocognitive disorders (TAND) including cognitive impairment, and psychiatric, behavioral, and sleep disorders.

To allow investigators time to plan and develop applications, NFRP is providing its strategic plan for award mechanisms to be offered in 2013 should funding become available. Congressional funds for the FY13 NFRP have not yet been appropriated, and this document is not to be construed as an obligation by the government; there is no guarantee of funding for these planned mechanisms. Areas of Emphasis: The FY13 NFRP encourages research projects applications that specifically address the critical needs of the NF community in the following areas of emphasis: Cognitive and social dysfunction in the setting of NF; Drug discovery for the treatment of NF; Heterogeneity of neurofibromas and other NF-related tumors using genomics, epigenetics, systems biology, or other similar approaches; Manifestations of NF post-adolescence; Novel disease markers such as imaging and proteomics of NF; Pain in the setting of NF.

The purpose of this FOA is to invite innovative research pre-applications from applicants who have an interest in submitting an application to "Stimulating Peripheral Activity to Relieve Conditions (SPARC): Technologies to Understand the Control of Organ Function by the Peripheral Nervous System (OT2)", companion announcement RFA-RM-16-003.  This NIH Funding Opportunity Announcement (FOA) solicits pre-applications to develop new and/or enhance existing tools and technologies to be used to elucidate the neurobiology and neurophysiology underlying autonomic control of organs in health or disease, which will ultimately inform next generation neuromodulation therapies. These two-year projects will facilitate technology development for neural mapping activities through the NIH SPARC Common Fund program.

The purpose of this FOA is to invite innovative research pre-applications from applicants who have an interest in submitting an application to "Stimulating Peripheral Activity to Relieve Conditions (SPARC): Technologies to Understand the Control of Organ Function by the Peripheral Nervous System (OT2)", companion announcement RFA-RM-16-003.  This NIH Funding Opportunity Announcement (FOA) solicits pre-applications to develop new and/or enhance existing tools and technologies to be used to elucidate the neurobiology and neurophysiology underlying autonomic control of organs in health or disease, which will ultimately inform next generation neuromodulation therapies. These two-year projects will facilitate technology development for neural mapping activities through the NIH SPARC Common Fund program.

This NIH Funding Opportunity Announcement (FOA) is part of the Stimulating Peripheral Activity to Relieve Conditions (SPARC) Common Fund program. This FOA solicits applications for support of research to gather critical data and answer critical questions on functional peripheral neuroanatomy of organs and reveal the organ function controlled by neural circuits.   Organs of interest include those where the peripheral neuroanatomy and functional neurobiology of the organ have been understudied, and which are not the subject of existing SPARC funding under RFA-RM-15-018 (see below).  

Leidos will match high-scoring, unfunded National Institutes of Health (NIH) proposals with private biomedical foundations and/or industries seeking to fund promising research. Foundations will have access to peer-reviewed research proposals that directly relate to their funding priorities, industry will have access to a rich pipeline of early stage and translational research proposals that align with its priorities, while applicants with strong research proposals will be provided with a second opportunity to secure funding. The foundations, industries, applicants, and NIH all will benefit from this synergy.